MedPath

A study to compare two different pedal wart treatments.

Not Applicable
Completed
Conditions
pedal warts
Skin - Other skin conditions
Infection - Other infectious diseases
Registration Number
ACTRN12613000062729
Lead Sponsor
Professor Reza Naraghi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
30
Inclusion Criteria

Eligible participants had one or more correctly diagnosed pedal cutaneous wart/s and were aged 18 years or over.

A registered podiatrist confirmed diagnosis when the pedal wart exhibited both the characteristic pinpoint bleeding with debridement and pain on lateral compression.

Exclusion Criteria

Participants were excluded from the study if they were prone to impaired healing (peripheral vascular disease, keloid scarring, anticoagulant therapy, haemophilia); were immunosuppressed or taking immunosuppressant drugs; were pregnant during the treatment period; had any previous adverse reactions to local anaesthetics; had suspected bacterial infection at the treatment site; were unable to give informed consent; were currently in a trial evaluating other treatments for their wart/s; were intending to treat their wart/s by other means during the trial period; had a primary pedal wart that was larger than 20mm in diameter; were receiving renal dialysis; had neuropathy; or were otherwise deemed not fit for treatment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome of this study was complete regression of the treated, primary wart at twelve weeks post initial treatment. <br><br>Regression was clinically defined as the return of normal skin striae.<br><br>High resolution, digital photographs were taken of the primary pedal wart at baseline and twelve weeks post initial treatment. A panel of two registered podiatrists, each with over 20 years experience, assessed the photographs. The panel members were blinded to the intervention and independently assessed whether the primary pedal wart had regressed. If the panel members’ outcomes conflicted, a third assessor was called upon to make the final decision.[twelve weeks post randomisation]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath